Methods of targeting kinases to treat cancer metastasis - Patent Application 20070123633
By targeting metastasis-specific kinases like ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, and ZC3HC1 with inhibitors, the method effectively inhibits brain metastases, addressing the clinical challenge of recurrence and limited treatment options.
Patent Information
- Application Number
- JP2022183795
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-08-11
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2038-08-10
AI Technical Summary
Current kinase inhibitors show little efficacy in inhibiting brain metastases, as they are developed based on targets in primary tumors and do not address metastasis-specific molecular targets, particularly for brain metastases, which are a significant clinical challenge with a high recurrence rate and limited treatment options.
Targeting specific kinases such as ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, and ZC3HC1 with inhibitors like siRNA, miRNA, or selective pharmacological inhibitors, administered via various routes, including intravenous, intrathecal, and intranasal, to inhibit brain metastasis in subjects with cancers like breast or lung cancer.
The method effectively inhibits brain metastasis growth, prolonging survival and improving quality of life by specifically targeting metastasis-specific kinases, even in cases where brain metastases are already present, and can be combined with other therapies like chemotherapy and radiation.
Smart Images

Figure 0007587860000005 
Figure 0007587860000006 
Figure 0007587860000007
Abstract
Description
[Technical field]
[0001] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 544,597, filed Aug. 11, 2018, the entire contents of which are incorporated herein by reference.
[0002] background This invention was made with Government support under Grant Nos. R01 CA112567 and R01 CA184836 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0003] 1. Field The present invention relates generally to the fields of molecular biology and medicine. More specifically, the present invention relates to methods of targeting kinases for the treatment of cancer, particularly brain metastases. [Background technology]
[0004] 2. Description of Related Technology Brain metastases affect millions of cancer patients, more than 10 times more than primary brain tumors. Major neoplastic diseases (e.g., melanoma, lung cancer, breast cancer, and colon cancer) have a high incidence of brain metastases. The one-year survival rate after diagnosis of brain metastases is less than 20%. Recently, advances in targeted cancer therapy (e.g., trastuzumab, T-DMl) have extended patient survival through better control of systemic disease. However, if patients later have a recurrence, they develop brain metastases at an increasing rate (e.g., more than 30%), presenting a new challenge in this era of successful targeted therapy. Current treatment options are limited and merely palliative for patients with brain metastases.
[0005] Kinases, which constitute a large family of enzymes, catalyze the transfer of the γ-phosphate of ATP to protein substrates. Reversible phosphorylation plays a paramount role in cell signaling processes and is regulated by kinases and phosphatases. Kinases are therefore important mediators of a myriad of signaling processes. Aberrant kinase activity has been implicated in cancer and metabolic, immunological, nervous system, and other disorders. As a result, kinases have emerged as an important class of drug targets for human diseases.
[0006] Many kinases are central to cancer cell signaling networks. Many efforts have succeeded in developing several FDA-approved inhibitors against various cancer-promoting kinases with significant clinical efficacy. These cancer-promoting kinases have been found to be valid drug targets in many disease settings, including trastuzumab (ErbB2), lapatinib (ErbB2 and EGFR), imatinib (BCR-Abl), gefitinib (EGFR), ibrutinib (BTK), and vemurafenib (BRAF). However, most existing kinase inhibitors are developed based on targets in primary tumors; no effort has been made to identify metastasis-specific, especially brain metastasis-specific, druggable molecular targets. Thus, although the current FDA-approved inhibitors against various cancer-promoting kinases may have significant clinical efficacy in inhibiting primary tumors, they show little or no efficacy in inhibiting brain metastases. Thus, to address the ever-growing clinical challenge of brain metastases, there is an unmet need to identify its drivers and target them therapeutically, prolonging survival and improving the quality of life of patients with brain metastases. Summary of the Invention
[0007] overview In a first aspect, the present disclosure provides a method for inhibiting brain metastasis in a subject with cancer, the method comprising administering an effective amount of a kinase inhibitor to the subject, the kinase inhibitor targets a kinase selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, TSSK6 and ZC3HC1.In some aspects, the subject is a human.In some aspects, the kinase inhibitor is siRNA or miRNA.In other aspects, the kinase inhibitor is a selective pharmacological inhibitor.
[0008] In some aspects, the cancer is breast cancer. In certain aspects, the breast cancer is further defined as triple-negative breast cancer. In other aspects, the cancer is lung cancer.
[0009] In some aspects, the subject was not known to have brain metastases prior to treatment. In other aspects, the subject was known to have one or more brain metastases prior to treatment.
[0010] In some aspects, the kinase inhibitor targets CDK5 or LIMK2. In some aspects, the kinase inhibitor of CDK5 is dinaciclib, bis-indole indirubin, (S)-CR8, kenpaullone, PHA-793887, AT7519, roscovitine, milciclib, SNS-032, or olomoucine. In some aspects, the kinase inhibitor of LIMK2 is BMS-5, Pyr-1, or T56-LIMKi.
[0011] In some aspects, the BTK kinase inhibitor is ibrutinib, acalabrutinib, ONO-4059, spebrutinib, BGB-3111, or HM71224. In some aspects, the CAMK4 kinase inhibitor is KN-93. In some aspects, the MAP2K7 kinase inhibitor is DTP3. In some aspects, the PMVK kinase inhibitor is CDDD_1633, CSDDD_2260, CSDDD_2419, or luteolin. In some aspects, the PRKCI kinase inhibitor is ridora or RXDX-108.
[0012] In some aspects, the kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, or by direct injection. In a specific aspect, the kinase inhibitor is administered intravenously. In a particular aspect, the kinase inhibitor is delivered directly to the brain. In some aspects, the kinase inhibitor is administered intrathecally or intranasally.
[0013] In additional aspects, the method further comprises administering at least a second therapeutic agent. In some aspects, the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, antiangiogenic therapy, or cytokine therapy. In certain aspects, the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, and / or metabolic regulation. In some aspects, the second therapeutic agent is administered simultaneously with the kinase inhibitor. In some aspects, the second therapeutic agent is administered sequentially to the kinase inhibitor.
[0014] In another embodiment, a method for treating brain metastasis in a subject with cancer is provided, the method comprising administering to a subject in need thereof an effective amount of a kinase inhibitor in combination with at least a second anti-cancer agent, the kinase inhibitor targets a kinase selected from the group consisting of PCTK1, SPHK1, FRK, MAPK12, ERK5, MAP2K7, UCK2, DAK, and PRKCD. In some aspects, the cancer is breast cancer. In certain aspects, the breast cancer is further defined as triple-negative breast cancer. In other aspects, the cancer is lung cancer. In some aspects, the subject was not known to have brain metastasis before treatment. In other aspects, the subject was known to have one or more brain metastases before treatment. In some aspects, the subject is a human.
[0015] In certain aspects, the kinase inhibitor targets PCTK1, SPHK1, MAPK12, or CDK5. In some aspects, the kinase inhibitor of MAPK12 is SB 203580, doramapimod, or LY2228820. In some aspects, the kinase inhibitor of PCTK1 is indirubin E804, dabrafenib, or rebastinib. In certain aspects, the kinase inhibitor of PCTK1 is rebastinib. In some aspects, the kinase inhibitor of SPHK1 is BML-258, SKI III, SKI 5C, MP A08, SKI 178, PF-543, fingolimod, or safingol. In certain aspects, the kinase inhibitor of SPHK1 is fingolimod or safingol. In some aspects, the kinase inhibitor of CDK5 is dinaciclib, PHA-793887, AT7519, CYC-065, roscovitine, or DCAM-422. In certain aspects, the kinase inhibitor of CDK5 is CYC-065 or DCAM-422.
[0016] In some aspects, the kinase inhibitor of ERK5 is ERK5-IN-1, BIX 02189, XMD17-109, or XMD 8-92. In some aspects, the kinase inhibitor of FRK is dasatinib, motesanib, dramapimod, pelitinib, sorafenib, vandetanib, canertinib, or imatinib. In some aspects, the kinase inhibitor of PAK4 is PF-3758309, LCH-7749944, glaucarbinone, KY-04031, KY-04045, 1-phenanthryl-tetrahydroisoquinoline derivatives, (-)-β-hydrastine, Inka1, GL-1196, or GNE-2861. In some aspects, the kinase inhibitor of UCK2 is flavokawain B or alpinetin.
[0017] In some aspects, the kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, or by direct injection. In certain aspects, the kinase inhibitor is administered intravenously. In some aspects, the kinase inhibitor is administered intrathecally or intranasally, such as for direct administration to the brain.
[0018] In some aspects, the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, antiangiogenic therapy, or cytokine therapy.In certain aspects, the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, and / or metabolic regulation.In some aspects, the second therapeutic agent is administered simultaneously with the kinase inhibitor.In other aspects, the second therapeutic agent is administered consecutively with the kinase inhibitor.
[0019] In a further embodiment, a method for inhibiting metastasis in a subject is provided, comprising administering a kinase inhibitor to a subject identified as having increased activity of at least two kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1, when compared to a control. In certain aspects, the increased activity is the result of increased expression level, post-translational modification, or subcellular localization. In some aspects, the increased activity is measured by increased expression level. In some aspects, the subject has breast cancer or lung cancer. In certain aspects, the metastasis is further defined as brain metastasis.
[0020] In some aspects, the subject is identified as having increased activity of at least five kinases (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 kinases) selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1 compared to a control. In some aspects, the subject is identified as having increased expression of at least 15 kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1, compared to a control. In some aspects, the subject is identified as having increased expression of at least 20 kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1, compared to a control.
[0021] In another embodiment, a composition is provided comprising an effective amount of a kinase inhibitor for treating brain metastasis in a subject having cancer, wherein the kinase inhibitor targets a kinase selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, TSSK6, and ZC3HC1.
[0022] Further provided herein is a composition comprising an effective amount of a kinase inhibitor and an anticancer agent for treating brain metastasis in a subject having cancer, wherein the kinase inhibitor targets a kinase selected from the group consisting of PCTK1, SPHK1, FRK, MAPK12, ERK5, MAP2K7, UCK2, DAK, and PRKCD.
[0023] In certain aspects of the above embodiments, the kinase inhibitor is selected from the group consisting of dinaciclib, bis-indole indolubin, (S)-CR8, kenpaullone, PHA-793887, AT7519, roscovitine, mirciclib, SNS-032, olomoucine, BMS-5, Pyr-1, T56-LIMKi, ibrutinib, acalabrutinib, ONO-4059, spebrutinib, BGB-3111, HM71224, DTP3, CDDD_1633, CSDDD_2260, CSDDD_2419, luteolin, ridora or RXDX-108, SB 203580, dramapimod, LY2228820, indirubin E804, dabrafenib, revastinib, BML-258, SKI III, SKI 5C, MP A08, SKI 178, PF-543, fingolimod, safingol, fingolimod, safingol, dinaciclib, PHA-793887, AT7519, CYC-065, DCAM-422, CYC-065 or DCAM-422, ERK5-IN-1, BIX 02189, XMD17-109, XMD 8-92, dasatinib, motesanib, dorampimod, pelitinib, sorafenib, vandetanib, canertinib, imatinib, PF-3758309, LCH-7749944, glaucarbinone, KY-04031, KY-04045, 1-phenanthryl-tetrahydroisoquinoline derivatives, (-)-β-hydrastine, Inka1, GL-1196, GNE-2861, flavokawain B or alpinetin.
[0024] In some aspects of the above embodiment, the cancer is breast cancer. In some aspects, the breast cancer is further defined as triple-negative breast cancer. In some aspects, the cancer is lung cancer. In some aspects, the subject was not known to have brain metastases before treatment. In other aspects, the subject was known to have one or more brain metastases before treatment. In some aspects, the subject is a human.
[0025] In some aspects, the method comprises administering at least a second anticancer agent.In some aspects, the second anticancer agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, antiangiogenesis therapy or cytokine therapy.In certain aspects, the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy or metabolic regulation.
[0026] [The present invention 1001] 1. A method for inhibiting brain metastasis in a subject having cancer, comprising: The method comprises administering to a subject an effective amount of a kinase inhibitor, wherein the kinase inhibitor targets a kinase selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, TSSK6, and ZC3HC1. [The present invention 1002] The method of claim 1001, wherein the cancer is breast cancer. [The present invention 1003] The method of claim 1002, wherein the breast cancer is further defined as triple negative breast cancer. [The present invention 1004] The method of claim 1001, wherein the cancer is lung cancer. [The present invention 1005] The method of claim 1001, wherein the subject was not known to have brain metastases prior to treatment. [The present invention 1006] The method of claim 1001, wherein the subject was known to have one or more brain metastases prior to treatment. [The present invention 1007] The method of claim 1001, wherein the subject is a human. [The present invention 1008] The method of claim 10, wherein the kinase inhibitor targets CDK5 or LIMK2. [The present invention 1009] The method of any one of claims 1 to 10, wherein the kinase inhibitor targets CDK5. [The present invention 1010] The method of claim 10, wherein the kinase inhibitor targets LIMK2. [The present invention 1011] The method of any one of claims 1 to 10, wherein the kinase inhibitor is an siRNA or miRNA. [The present invention 1012] The method of any one of claims 1 to 10, wherein the kinase inhibitor is a selective pharmacological inhibitor. [The present invention 1013] 1009. The method of claim 1009, wherein the kinase inhibitor of CDK5 is dinaciclib, bis-indole indirubin, (S)-CR8, kempauron, PHA-793887, AT7519, roscovitine, milciclib, SNS-032, or olomoucine. [The present invention 1014] The method of the present invention 1010, wherein the kinase inhibitor of LIMK2 is BMS-5, Pyr-1, or T56-LIMKi. [The present invention 1015] The method of claim 1001, wherein the kinase inhibitor of BTK is ibrutinib, acalabrutinib, ONO-4059, spebrutinib, BGB-3111, or HM71224. [The present invention 1016] The method of the present invention 1001, wherein the kinase inhibitor of CAMK4 is KN-93. [The present invention 1017] 1001. The method of claim 1001, wherein the kinase inhibitor of MAP2K7 is DTP3. [The present invention 1018] The method of the present invention 1001, wherein the kinase inhibitor of PMVK is CDDD_1633, CSDDD_2260, CSDDD_2419, or luteolin. [The present invention 1019] The method of claim 1001, wherein the kinase inhibitor of PRKCI is RIDORA or RXDX-108. [The present invention 1020] The method of any of claims 1001 to 1019, wherein the kinase inhibitor is delivered directly to the brain. [The present invention 1021] The method of any of claims 1001 to 1019, wherein the kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, or by direct injection. [The present invention 1022] The method according to any one of claims 1001 to 1019, wherein the kinase inhibitor is administered intravenously. [The present invention 1023] The method according to any one of claims 1001 to 1019, wherein the kinase inhibitor is administered intrathecally or intranasally. [The present invention 1024] The method of any of claims 1001 to 1019, further comprising the step of administering at least a second therapeutic agent. [The present invention 1025] The method of claim 1024, wherein the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, antiangiogenic therapy, or cytokine therapy. [The present invention 1026] The method of claim 1024, wherein the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, and / or metabolic modulation. [The present invention 1027] The method of claim 1024, wherein the second therapeutic agent is administered simultaneously with the kinase inhibitor. [The present invention 1028] The method of any one of claims 10 to 24, wherein the second therapeutic agent is administered sequentially to the kinase inhibitor. [The present invention 1029] 1. A method for treating brain metastasis in a subject with cancer, comprising: The method comprises administering to a subject in need thereof an effective amount of a kinase inhibitor in combination with at least a second anti-cancer agent, wherein the kinase inhibitor targets a kinase selected from the group consisting of PCTK1, SPHK1, FRK, MAPK12, ERK5, MAP2K7, UCK2, DAK, and PRKCD. [The present invention 1030] The method of claim 1029, wherein the cancer is breast cancer. [The present invention 1031] The method of claim 1030, wherein the breast cancer is further defined as triple negative breast cancer. [The present invention 1032] The method of claim 1029, wherein the cancer is lung cancer. [The present invention 1033] The method of claim 1001, wherein the subject was not known to have brain metastases prior to treatment. [The present invention 1034] The method of claim 1029, wherein the subject was known to have one or more brain metastases prior to treatment. [The present invention 1035] The method of claim 1029, wherein the subject is a human. [The present invention 1036] The method of claim 1029, wherein the kinase inhibitor targets PCTK1, SPHK1, MAPK12, or CDK5. [The present invention 1037] The method of claim 1029, wherein the kinase inhibitor targets PCTK1. [The present invention 1038] The method of claim 1029, wherein the kinase inhibitor targets SPHK1. [The present invention 1039] The method of claim 1029, wherein the kinase inhibitor targets MAPK12. [The present invention 1040] The method of claim 1029, wherein the kinase inhibitor of MAPK12 is SB 203580, doramapimod, or LY2228820. [The present invention 1041] 1029. The method of claim 1029, wherein the kinase inhibitor of PCTK1 is indirubin E804, dabrafenib, or rebastinib. [The present invention 1042] The method of the present invention, wherein the kinase inhibitor of PCTK1 is revastinib. [The present invention 1043] 1029. The method of claim 1029, wherein the kinase inhibitor of SPHK1 is BML-258, SKI III, SKI 5C, MP A08, SKI 178, PF-543, fingolimod, or safingol. [The present invention 1044] The method of claim 1029, wherein the kinase inhibitor of SPHK1 is fingolimod or safingol. [The present invention 1045] 1029. The method of claim 1029, wherein the kinase inhibitor of CDK5 is dinaciclib, PHA-793887, AT7519, CYC-065, or DCAM-422. [The present invention 1046] 1029. The method of claim 1029, wherein the kinase inhibitor of CDK5 is CYC-065 or DCAM-422. [The present invention 1047] The method of claim 1029, wherein the kinase inhibitor of ERK5 is ERK5-IN-1, BIX 02189, XMD17-109, or XMD 8-92. [The present invention 1048] The method of claim 1029, wherein the FRK kinase inhibitor is dasatinib, motesanib, dorampimod, pelitinib, sorafenib, vandetanib, canertinib, or imatinib. [The present invention 1049] 1029. The method of claim 1029, wherein the kinase inhibitor of PAK4 is PF-3758309, LCH-7749944, glaucarbinone, KY-04031, KY-04045, 1-phenanthryl-tetrahydroisoquinoline derivatives, (-)-β-hydrastine, Inka1, GL-1196, or GNE-2861. [The present invention 1050] The method of claim 1029, wherein the kinase inhibitor of UCK2 is flavokawain B or alpinetin. [The present invention 1051] The method of any of claims 1029 to 1051, wherein the kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, or by direct injection. [The present invention 1052] The method according to any one of claims 1029 to 1051, wherein the kinase inhibitor is administered intravenously. [The present invention 1053] The method of any of claims 1029 to 1051, wherein the kinase inhibitor is administered intrathecally or intranasally. [The present invention 1054] The method of any of claims 1029 to 1051, wherein the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, antiangiogenic therapy, or cytokine therapy. [The present invention 1055] The method of any of claims 1029 to 1051, wherein the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, and / or metabolic regulation. [The present invention 1056] The method of any of claims 1029 to 1051, wherein the second therapeutic agent is administered simultaneously with the kinase inhibitor. [The present invention 1057] The method of any of claims 1029 to 1051, wherein the second therapeutic agent is administered sequentially to the kinase inhibitor. [The present invention 1058] 1. A method for inhibiting metastasis in a subject, comprising: The method comprises administering a kinase inhibitor to a subject identified as having increased activity of at least two kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1, as compared to a control. [The present invention 1059] The method of claim 1058, wherein the increased activity is the result of increased expression levels, post-translational modification, or subcellular localization. [The present invention 1060] The method of claim 1059, wherein the increased activity is measured by increased expression levels. [The present invention 1061] The method of claim 1058, wherein the subject has breast cancer or lung cancer. [The present invention 1062] The method of claim 1058, wherein the metastasis is further defined as brain metastasis. [The present invention 1063] The method of claim 1058, wherein the subject is identified as having increased activity of at least five kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1 compared to a control. [The present invention 1064] The method of claim 1058, wherein the subject is identified as having increased expression of at least 15 kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1 compared to a control. [The present invention 1065] The method of claim 1058, wherein the subject is identified as having increased expression of at least 20 kinases selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12, MAPK7, PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1 compared to a control. [The present invention 1066] A composition comprising an effective amount of a kinase inhibitor for treating brain metastasis in a subject having cancer, wherein the kinase inhibitor targets a kinase selected from the group consisting of ADCK4, BTK, CAMK4, CDK5, CDK5R1, CLK3, LIMK2, PAK4, PMVK, PRKACB, PRKACG, PRKCI, TSSK6, and ZC3HC1. [The present invention 1067] A composition comprising an effective amount of a kinase inhibitor and an anticancer drug for treating brain metastasis in a subject having cancer, wherein the kinase inhibitor targets a kinase selected from the group consisting of PCTK1, SPHK1, FRK, MAPK12, ERK5, MAP2K7, UCK2, DAK, and PRKCD. [The present invention 1068] The composition of any one of claims 1066 to 1067, wherein the cancer is breast cancer. [The present invention 1069] The method of any one of claims 1066 to 1067, wherein the breast cancer is further defined as triple negative breast cancer. [The present invention 1070] The method of any one of claims 1066 to 1067, wherein the cancer is lung cancer. [The present invention 1071] The method of claim 1066 or 1067, wherein the subject was not known to have brain metastases prior to treatment. [The present invention 1072] The method of any one of claims 1066 to 1067, wherein the subject was known to have one or more brain metastases prior to treatment. [The present invention 1073] The method of any one of claims 1066 to 1067, wherein the subject is a human. [The present invention 1074] The method of claim 1066, further comprising the step of administering at least a second anticancer agent. [The present invention 1075] The method of any one of claims 1067 to 1074, wherein the second anti-cancer agent is chemotherapy, radiation therapy, gene therapy, surgery, hormone therapy, anti-angiogenic therapy, or cytokine therapy. [The present invention 1076] The method of any one of claims 1067 to 1074, wherein the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, or metabolic modulation. Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]
[0027] The drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The present invention may be better understood by reference to one or more of the drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1] Schematic diagram of in vivo kinome screening for drivers of brain metastasis growth. MDA-MB-231 parental cells (231p) stably expressing luciferase, GFP, and a pool of up to 24 kinases (231p.Luciferase.GFP) were mixed with 231p cells expressing TdTomato and empty pWZL-Neo-Myr-Flag-DEST vector (231p.TdTomato). Cells were mixed in a 3:1 ratio of kinase pool:vector, and 2 x 106 cells were injected into the carotid artery of nude mice. When animals showed neurological symptoms and their heads were determined by IVIS to be highly luciferase positive, mice were sacrificed and brain lesions were isolated using a dissecting microscope based on GFP positivity. A portion of the lesions was directly subjected to RNA extraction, while the remainder was dissociated and cells were cultured in vitro as passage 0. gDNA was extracted from the recovered cells and kinase vector sequences were amplified by targeted PCR. This DNA was sequenced by MiSeq to provide a quantitative readout of in vivo selection. [Diagram 2]Example of relative sequence enrichment after in vivo selection. Comparison of kinase sequence read counts before and after in vivo selection demonstrated significant loss of most sequences in vivo, with significant positive selection of those kinases considered "hits." Coverage plots were generated in MiSeq Reporter. [Diagram 3] Confirmation of kinase overexpression-driven brain metastasis growth in vivo. An in vivo imaging system (IVIS) was used to quantify the luminescence signal generated by luciferase-expressing cancer cells. 1 x 105 cells were injected per animal on day 0, and luciferase signal was normalized to day 1. (A) Comparison of CDK5-, PCTK1-, MAPK12-, and MARK4-overexpressing brain metastasis growth with corresponding vector controls shows that all kinases except MARK4 are confirmed drivers of brain metastasis. (B) Comparison of SPHK1-overexpressing cancer cells with vector control cells shows that SPHK1 indeed enhances brain metastasis growth. [Figure 4] Kinase overexpression in MDA-MB-231 significantly shortens survival in an experimental brain metastasis model. Mice injected with kinase overexpressing cells or the corresponding vector cells were compared for their brain metastasis-specific survival. (A) PCTK1 overexpression shortened survival from a median of 128 days to 60 days. Survival curves were significantly different (p=0.0004) according to the Mantel-Cox log-rank test. (B) SPHK1 overexpression shortened survival from a median of 131 days to 102.5 days. (C) CDK5 overexpression shortened survival from a median of 128 days to 70 days. [Diagram 5] PCTK1 knockdown significantly delays death in the HCC1954Br experimental brain metastasis model. (A) Western blot showing the efficiency of shRNA-mediated knockdown of PCTK1 before intracarotid injection. (B) Survival analysis of nude mice injected with 1 x 105 cells shows that PCTK1 knockdown extends median survival from 57.5 days to 91 days. [Figure 6]SPHK1 knockdown significantly delays death in the MDA-MB-435 experimental brain metastasis model. (A) Western blot showing the efficiency of shRNA-mediated knockdown of SPHK1 prior to intracarotid injection. (B) Survival analysis of nude mice injected with 1 x 105 cells shows that SPHK1 knockdown extends median survival from 57.5 days to 77 days. [Figure 7] MAPK12 knockdown significantly delays brain metastasis growth at an early stage in the 4T1 experimental brain metastasis model. (A) Western blot showing the efficiency of shRNA-mediated knockdown of MAPK12 before intracarotid injection. (B) Comparison of MAPK12 knockdown cancer cells with vector control cells shows that MAPK12 knockdown delays brain metastasis growth. (C) Survival analysis of BALB / c mice injected with 4T1 cells shows that MAPK12 knockdown extends median survival from 15 to 19 days. Survival curves were significantly different (p=0.02) according to the Mantel-Cox log-rank test. [Figure 8] CDK5 knockdown reduces cell proliferation in vitro in hypoxic conditions and significantly delays death in the EO771 experimental brain metastasis model in a CD8 T cell-dependent manner. (A) Western blot showing the efficiency of shRNA-mediated knockdown of CDK5 in EO771 cells. (B) MTT assay demonstrated a significant decrease in in vitro cell proliferation in CDK5 knockdown cells in hypoxic conditions when compared to vector control cells. (C) Survival analysis of C57BL / 6 mice injected with EO771 cells shows that CDK5 knockdown extends median survival from 19 days to 23.5 days. (D) Survival analysis of C57BL / 6 mice injected with either control or CDK5 knockdown EO771 cells shows that there is no significant difference in mouse survival between these two groups when CD8-T cells are depleted using αCD8 antibody. [Figure 9]CDK5 knockdown in EO771 cells makes them less sensitive to roscovitine and more sensitive to T cell cytotoxicity. (A) Cell viability curves demonstrating that CDK5 knockdown in EO771 cells makes them less sensitive to the CDK5 inhibitor roscovitine compared to control cells. (B) Cytotoxic T cell killing assays showed that CDK5 knockdown in E0771 cells makes them more sensitive to activated T cell cytotoxicity compared to EO771 control cells. T cells were activated with CD3 / CD28 antibodies (100 ng / mL) and IL-2 (10 ng / mL) prior to co-culture with tumor cells. [Figure 10] LIMK2 overexpression promotes cell proliferation in vitro under hypoxic conditions. (A) Western blot showing the overexpression efficiency of LIMK2 in MDA-MB-231 cells. (B) MTT assay demonstrated a significant increase in in vitro cell proliferation under hypoxic conditions when LIMK2 was overexpressed compared to vector control cells. [Figure 11] LKB1 overexpression promotes cell proliferation in vitro in both normoxic and hypoxic conditions. (A) Western blot showing the efficiency of overexpression of LKB1 in MDA-MB-231 cells. (B) MDA-MB-231 cells in which LKB1 was overexpressed demonstrated a significant increase in in vitro cell proliferation in normoxic conditions when compared to vector control cells, as shown in an MTT assay. (C) MDA-MB-231 cells in which LKB1 was overexpressed demonstrated a significant increase in in vitro cell proliferation in hypoxic conditions when compared to vector control cells, as shown in an MTT assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] Description of Exemplary Embodiments To identify driver kinases of brain metastasis for use in treating brain metastasis by exploiting kinase druggability, this study performed a random in vivo screen of the human kinome to discover novel kinases that promote breast cancer brain metastasis and may serve as therapeutic targets for effective inhibition of brain metastasis. While currently available kinase targets were identified by their role in promoting cancer cell growth in cell culture dishes, the kinases identified here arose from a functional in vivo screen specifically looking for drivers of brain metastasis in animals. Thus, the targets identified by this method play a role specifically in the growth of brain metastases.
[0029] Specifically, the 354-kinase library was split into 17 pools of 21 kinases each in the MDA-MB-231 human triple-negative breast cancer cell line, and the resulting cells were injected into the carotid artery of nude mice to induce experimental brain metastases. Several of these kinase pools dramatically increased brain metastasis-specific death compared to 231 vector control cells. Next-generation sequencing (NGS) and genetic analysis identified certain kinases that enhanced these aggressive brain metastases in vivo. These efforts have revealed more than 20 brain metastasis-promoting kinases, including ADCK4 (COQ8B), BTK, CAMK4, CDK5, CDK5R1, CLK3, DAK, FRK, LIMK2, MAP2K7, MAPK12 (p38γ), MAPK7 (ERK5), PAK4, PCTK1, PMVK, PRKACB, PRKACG, PRKCD, PRKCI, SPHK1, TSSK6, UCK2, and ZC3HC1 (Table 1 ).
[0030] To further test these kinases, we genetically knocked down some of the kinases and tested the effect of targeting these identified brain metastasis driver kinases for inhibition of brain metastasis. Indeed, knocking down some of the top hits inhibited experimental brain metastasis and significantly extended the survival of mice with brain metastases. Specifically, knocking down kinases such as PCTK1, SPHK1, MAPK12, and CDK5 reduced cell proliferation and delayed brain metastasis growth in human cancer cell models and in the early stages of the 4T1 mouse breast tumor model of experimental brain metastasis.
[0031] The effectiveness of targeting some of these kinases identified in the screening to inhibit brain metastasis was also assayed in this study by overexpressing the kinases in experimental brain metastasis mouse models. Overexpression of CDK5, PCTK1, MAPK12, LIMK2, and SPHK1 increased brain metastasis growth. In particular, overexpression of kinases such as SPHK1, PCTK1, LIMK2, and CDK5 shortened survival in experimental brain metastasis mouse models. Therefore, the kinases identified in the screening herein can be targeted to inhibit brain metastasis, such as breast cancer brain metastasis.
[0032] Thus, in some embodiments, the present disclosure provides a method for targeting the brain metastasis-driving kinases identified from kinome screening for effective inhibition of brain metastasis.The kinases identified herein can be targeted by inhibitors, including genetic inhibitors, chemical inhibitors, immunological inhibitors, and metabolic inhibitors.Kinase inhibitors can be used in combination with current standard treatments for brain metastasis, such as radiation therapy, chemotherapy, immunotherapy, and metabolic modulation.
[0033] I. Definition As used in the specification, "a" or "an" may mean one or more. As used in the claims, when used in conjunction with the word "comprising," the words "a" or "an" may mean one or more than one.
[0034] The use of the term "or" in the claims is used to mean "and / or" unless expressly indicated to refer only to alternatives or the alternatives are not mutually exclusive, although the disclosure supports a definition that refers only to alternatives and "and / or." As used herein, "another" can mean at least a second or more. The terms "about," "substantially," and "approximately" generally mean the stated value plus or minus 5%.
[0035] As used herein, the term "patient" or "subject" refers to a living mammalian organism, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or a transgenic species thereof. In some embodiments, the patient or subject is a primate. Non-limiting examples of human patients are adults, juveniles, infants, and fetuses.
[0036] A "treatment step" or treatment of a disease or condition refers to carrying out a protocol that may include administering one or more drugs to a patient in an attempt to alleviate the signs or symptoms of the disease. Desirable effects of treatment include reducing the rate of disease progression, improving or mitigating the disease state, and remission or improving prognosis. Alleviation can occur before the appearance of signs or symptoms of a disease or condition, as well as after their appearance. Thus, a "treatment step" or "treatment" can include a "prophylactic step" or "prevention" of a disease or undesirable condition. Furthermore, a "treatment step" or "treatment" does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes protocols that have only a minor effect on a patient.
[0037] The term "effective," as that term is used in the specification and / or claims, means adequate to achieve a desired, expected, or intended result. An "effective amount," "therapeutically effective amount," or "pharmacologically effective amount," when used in the context of treating a subject or patient with a compound, means the amount of the compound that, when administered to a subject or patient for treating or preventing a disease, is sufficient to effect such treatment or prevention of the disease.
[0038] "Prevention" or "preventing" includes (1) preventing the onset of disease in a subject or patient who may be at risk for and / or predisposed to the disease, but who has not yet experienced or displayed any or all of the pathology or symptoms of the disease, and / or (2) delaying the onset of disease pathology or symptoms in a subject or patient who may be at risk for and / or predisposed to the disease, but who has not yet experienced or displayed any or all of the pathology or symptoms of the disease.
[0039] As generally used herein, "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues, organs, and / or body fluids of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio.
[0040] "Pharmaceutically acceptable salt" refers to a salt of the compound disclosed herein that is pharmaceutically acceptable as defined above and has the desired pharmacological activity. Such salts include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or salts with 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acid, aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, Included among the acid addition salts are those formed with organic acids such as ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acids, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butyl acetic acid, trimethyl acetic acid, and the like. Pharmaceutically acceptable salts also include base addition salts that may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. It should be recognized that the particular anion or cation forming part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable.Additional examples of pharma- ceutically acceptable salts and methods for their preparation and use are provided in Handbook of Pharmaceutical Salts: Properties, and Use (PH Stahl & CG Wermuth eds., Verlag Helvetica Chimica Acta, 2002).
[0041] A "pharmaceutically acceptable carrier", "drug carrier", or simply "carrier" is a pharma- ceutically acceptable substance formulated with an active ingredient drug that is involved in the carrying, delivery, and / or transport of a chemical agent. Drug carriers can be used to improve the delivery and efficacy of drugs, including, for example, controlled release technologies to regulate drug bioavailability, reduce drug metabolism, and / or reduce drug toxicity. Some drug carriers can increase the efficacy of drug delivery to a particular target site. Examples of carriers include liposomes, microspheres (e.g., made from poly(lactic-co-glycolic acid)), albumin microspheres, synthetic polymers, nanofibers, protein-DNA complexes, protein conjugates, red blood cells, virosomes, and dendrimers.
[0042] An "inhibitor" or "antagonist" is a compound that reduces or inhibits the activity of a given target, such as a kinase.
[0043] As used herein, the term "protein kinase" or "kinase" is used according to its normal meaning and refers to an enzyme that can catalyze the transfer of a phosphate group from a high-energy phosphate donor molecule to a specific substrate, such as the phosphorylation of an amino acid residue, e.g., an amino acid residue on a protein, or an amino alcohol. Typically, a specific serine, threonine, or tyrosine residue is phosphorylated. Thus, protein kinases include serine protein kinases, threonine protein kinases, and tyrosine protein kinases. An "inhibitor of protein kinase" or "kinase inhibitor" is a compound or agent that reduces the activity of a protein kinase. In some embodiments, a "kinase inhibitor" is a compound that reduces the activity of a protein kinase by binding to the protein kinase. Thus, a "kinase inhibitor" can inhibit the activity of an enzyme in a competitive or non-competitive manner.
[0044] "Control" or "control experiment" is used according to its ordinary meaning to refer to an experiment in which an experimental subject or agent is treated identically in a parallel experiment except for the omission of the experimental procedure, agent, or variable. In some cases, a control is used as a standard of comparison in the evaluation of an experimental effect.
[0045] "Contacting" is used according to its ordinary meaning and refers to a process that allows at least two different species (e.g., compounds, including biomolecules, or cells) to come close enough to react, interact, or physically touch. However, it should be understood that the resulting reaction product may be generated directly from the reaction between the added reagents, or from an intermediate derived from one or more added reagents that may be generated in the reaction mixture. The term "contacting" includes incubating an inhibitor with a kinase.
[0046] As defined herein, the terms "inhibit", "inhibit", "inhibiting" and the like in reference to kinase-inhibitor interactions refer to adversely affecting (e.g., decreasing) the activity of a kinase compared to the activity of the kinase in the absence of the inhibitor. Thus, inhibition includes, at least in part, partially or completely blocking stimulation, reducing, preventing or delaying activation, or inactivating, blunting or downregulating signal transduction. Similarly, an "inhibitor" is a compound that inhibits kinase activity, partially or completely blocks stimulation, reduces, prevents or delays activation, or inactivates, blunts or downregulates signal transduction, for example, by binding.
[0047] By "selective" is intended an affinity for a given kinase that is at least 5-fold to 10-fold, preferably 25-fold, more preferably 100-fold, and even more preferably 150-fold greater than the affinity for other kinases.
[0048] As used herein, the phrase "ATP-binding pocket" refers to the active site of a kinase that binds ATP. The active site of a kinase to which ATP binds is a set of amino acid residues that can interact with and / or bind to an ATP molecule or an ATP-competitive inhibitor.
[0049] As used herein, the term "mutated" refers to a kinase having a non-natural (e.g., non-wild-type) amino acid sequence. A mutant kinase is typically a recombinant (e.g., engineered) kinase. In some embodiments, as described below, a mutant kinase has a cysteine residue substitution at a gatekeeper amino acid position. As used herein, the term "unmutated" refers to a corresponding kinase (e.g., a native or wild-type sequence) in which a mutation (e.g., a cysteine residue is substituted for a gatekeeper amino acid position) is not present. Thus, in some cases, unmutated refers to a wild-type or natural kinase. In some other cases, the corresponding kinase is another recombinant kinase with a similar but different substitution.
[0050] A "metastasis" is an area of cancer cells that is different from the primary tumor location, resulting from the dissemination of cancer cells from the primary tumor to other parts of the body. Upon diagnosis of the primary mass, the subject may be monitored for the presence of metastasis. Metastasis is most often detected by the use of magnetic resonance imaging (MRI) scans, computed tomography (CT) scans, blood and platelet counts, liver function studies, chest X-rays, and bone scans, alone or in combination, in addition to monitoring specific symptoms. A "detectable" metastasis is a cluster of cells that may be identifiable by magnetic resonance imaging, computed tomography, or positron emission tomography. In one non-limiting embodiment, a cluster of metastatic cells is at least about 1 x 10 7 In some embodiments, detectable metastases may include clusters of cells having a size greater than about 5 mm or about 10 mm.
[0051] The term "small molecule" is a term of the art and includes molecules with a molecular weight of less than about 1000 or less than about 500. In one embodiment, small molecules do not exclusively contain peptide bonds. In another embodiment, small molecules are not oligomeric. Exemplary small molecule compounds that can be screened for activity include, but are not limited to, peptides, peptidomimetics, nucleic acids, carbohydrates, small organic molecules (e.g., polyketides) (Cane et al., 1998), and natural product extract libraries. In another embodiment, the compound is a small, organic, non-peptidic compound. In a further embodiment, the small molecule is not biosynthetic.
[0052] II. Target Kinase In some embodiments, the present disclosure provides a method of treating (e.g., inhibiting or reducing) metastasis, such as brain metastasis, by administering an inhibitor of a kinase identified as a metastasis-promoting kinase (Table 1) by the in vivo kinase screen of this study. The treatment can be performed in a subject with a primary tumor to inhibit the occurrence of metastasis, particularly brain metastasis. In other aspects, the subject can be diagnosed with a metastatic tumor, such as brain metastasis, and the treatment reduces brain metastasis, for example, by at least 10%, particularly 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100%.
[0053] Therapeutic agents, such as kinase inhibitors, that can reduce the level of metastasis-promoting kinase include those generally known in the art, such as antisense nucleic acid, shRNA, siRNA, small molecule, polypeptide, antibody or antibody fragment, polynucleotide, carbohydrate including polysaccharide, lipid, drug, and their mimetics, derivatives, and combinations.In certain aspects, kinase is inhibited by a kinase inhibitor that is selective for a particular kinase.Exemplary selective kinase inhibitors for each kinase in Table 1 are disclosed herein, but any selective kinase inhibitor known in the art may be used for the present method.
[0054] Table 1. In vivo enriched kinase sequences determined by NGS sequencing. TIFF0007587860000001.tif137159
[0055] A. PCTK1 (CDK16) The serine / threonine-protein kinase PCTAIRE-1 (PCTK1) gene, also called cyclin-dependent kinase 16 (CDK16), encodes a kinase that plays a role in vesicle-mediated transport processes and exocytosis. It also regulates neuronal differentiation and dendritic development. PCTK1 can be inhibited by RNAi and / or pharmacological inhibitors selective for PCTK1. For example, one inhibitor selective for PCTK1 that can be used in the present method is indirubin E804 or its analogs (Hoessel et al., 1999; Cweik et al., 2015; both incorporated herein by reference). The inhibitor binds to the ATP site by interacting with the hinge region through H-bond interactions. Other inhibitors that can be used to inhibit PCTK1 include type I kinase inhibitors, such as triazolo-diamine compound Cdk1 / 2 inhibitor III, arterpaullone, 2-cyanoethyl, indirubin E804 and aminopyrimidinyl compound Cdk2 / 9 inhibitor.CDK2 inhibitors, such as oxindole GW300657X and GW416981X, and pyrazolo[1,5-b]pyridazine compound GW779439X, can also be used to inhibit PCTK1.
[0056] In certain aspects, dabrafenib or revastinib is used to inhibit PCTK1. Revastinib is a multi-targeting type II kinase inhibitor developed to inhibit BCR-ABL as well as drug-resistant gatekeeper mutant ABL. Dabrafenib is a mutant BRAF approved for clinical use in advanced melanoma. V600E In one specific aspect, the inhibitor of PCTK1 is revastinib.
[0057] Indirubin E804 can be synthesized by the following method. Briefly, to a solution of indoxyl acetate 2 (5.00 g, 28.5 mmol) in anhydrous methanol (70 mL) under nitrogen, isatin 1 (4.20 g, 28.8 mmol) and sodium carbonate (6.50 g, 61.3 mmol) are added. After stirring for 30 min and standing for 24 h, the slurry is filtered and washed with cold methanol and cold water. The resulting indirubin 3 (2.50 g, 9.5 mmol) and hydroxylamine hydrochloride (1.7 g, 24.7 mmol) are refluxed together in pyridine (60 mL) for 1.5 h. The mixture is then poured into a 1 M solution of hydrochloric acid (100 mL). The red / orange precipitate is filtered off, redissolved in 1 M sodium hydroxide (70 mL) and reprecipitated with 1 M hydrochloric acid (150 mL). The crude product is filtered, dried, and recrystallized from ethanol / water (7:2) to give the product as bright red / orange crystals. Finally, indirubin-3'-oximine 4 (55.4 mg, 0.20 mmol) and 4-bromobutane-1,2-diol 5 (40.1 mg, 0.24 mmol) are dissolved in anhydrous dimethylformamide (1.5 mL). To this is added triethylamine (33 μL, 0.24 mmol). The reaction is stirred under nitrogen for 4 hours, after which the solvent is removed in vacuo to give a crude brown oil which is purified by column chromatography to give the product as a red solid (36 mg, 41% yield).
[0058] B.SPHK1 Sphingosine kinase (SPHK1) is a key enzyme that promotes cell proliferation and survival and regulates the S1P / ceramide rheostat. Non-isoenzyme specific inhibitors of SPHK, such as L-threo-dihydrosphingosine (safingol) and N,N-dimethylsphingosine (DMS), can be used in the present method. In some aspects, SPHK1 can be inhibited by any of the following inhibitors: BML-258 as described in U.S. Pat. No. 8,372,888; 3-(4-chloro-phenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)-amide, [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol (PF-543), as described in U.S. Patent Application Publication No. 20080167352; sphingosine kinase inhibitor 2 (SKI II; 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol); SKI 5C (CAY10621); N,N-dimethylsphingosine ((2S,3R,4E)-2-(dimethylamino)-4-octadecene-1,3-diol); MP A08 (4-methyl-N-[2-[[[2-[[(4-methylphenyl)sulfonyl]amino]phenyl]imino]methyl]phenyl]benzenesulfonamide), SKI 178 (N'-(1-(3,4-dimethoxyphenyl)ethylidene)-3-(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide), or an analog, derivative, or pharma- ceutically acceptable salt thereof. In certain aspects, the inhibitor of SPHK1 is fingolimod (Gilenya) or safingol.
[0059] C. MAPK12 (p38γ) Mitogen-activated protein kinase 12 (MAP kinase 12), also known as extracellular signal-regulated kinase 6 (ERK6) or stress-activated protein kinase 3 (SAPK3), is an enzyme encoded by the MAPK12 gene in humans. Activation of members of the mitogen-activated protein kinase family is the major mechanism for the transmission of extracellular signals. Stress-activated protein kinases are a subclass of MAP kinases. The protein encoded by this gene functions as a signal transducer during the differentiation of myoblasts into myotubes. MAPK12 can be inhibited by SB 203580, Dorampimod (BIRB 796), LY2228820, or other inhibitors of MAPK12 known in the art.
[0060] D. CDK5 and CDK5R1 Cell division protein kinase 5 is an enzyme that is encoded by the CDK5 gene in humans. CDK5 is required for proper development of the brain, and in order to be activated, CDK5 must associate with CDK5R1 or CDK5R2. CDK5 or CDK5R1 can be inhibited in the present method by dinaciclib (SCH727965), bis-indole indirubin, (S)-CR8, kenpaullone, PHA-793887, AT7519, roscovitine (seliciclib, CYC202), milciclib (PHA-848125), SNS-032 (BMS-387032), or olomoucine. In certain aspects, the inhibitor of CDK5 is CYC-065 or DCAM-422.
[0061] E.LIMK2 LIM kinase 2 (LIMK2) is a regulator of actin cytoskeleton. LIMK2 phosphorylates cofilin, a member of actin depolymerizing factor (ADF) family, and thus inactivates it. Exemplary inhibitors of LIMK2 include, but are not limited to, BMS-5 (CAS No. 1338247-35-0), Pyr-1 (LIMNIB), damnacanthal, Par-3, T56-LIMKi, and LX7101. LX7101 is a pyrrolopyrimidine-based locally delivered inhibitor of LIM domain kinase 2 (LIMK2), a kinase involved in the regulation of intraocular pressure.
[0062] F.ADCK4(COQ8B) Coenzyme Q8B (COQ8B) or AarF domain-containing protein kinase 4 (ADCK4) is a lipid-soluble electron transporter for aerobic cellular respiration. ADCK4 can be inhibited by RNAi or inhibitors known in the art.
[0063] G.BTK Bruton's tyrosine kinase (Btk or BTK), also known as tyrosine-protein kinase BTK, is an enzyme encoded by the BTK gene in humans. BTK is a kinase that plays a role in B cell development. The function of BTK in the signaling pathway activated by the binding of the B cell receptor (BCR) and FCER1 on mast cells is well established. Functional mutations in BTK in humans result in primary immunodeficiencies characterized by defects in B cell development with a block between the pro- and pre-B cell stages. Exemplary inhibitors of BTK include, but are not limited to, ibrutinib (PCI-32765), acalabrutinib, ONO-4059, spebrutinib (AVL-292, CC-292), BGB-3111, and HM71224.
[0064] H.CAMK4 Calcium / calmodulin-dependent protein kinase type IV is an enzyme that is encoded by the CAMK4 gene in humans. The product of this gene belongs to the serine / threonine protein kinase family and the Ca2+ / calmodulin-dependent protein kinase subfamily. This enzyme is a multifunctional serine / threonine protein kinase with limited tissue distribution that is involved in transcriptional regulation in lymphocytes, neurons and male germ cells. An exemplary inhibitor of CAMK4 is KN-93 (N-[2-[[[3-(4-chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide).
[0065] I.CLK3 CDC-like kinase 3 (CLK3) is a nuclear dual specificity kinase that regulates the nuclear distribution of the serine / arginine-rich (SR) family of splicing factors.An exemplary inhibitor of CLK3 is KH-CB19.Other inhibitors that can be used include R547, A-674563, NVP-TAE684, and AT-7519.
[0066] J.D.A.K. Triokinase / FMN cyclase or dihydroxyacetone kinase 2 homolog (DAK) is an enzyme that is encoded by DAK gene in humans.DAK phosphorylates dihydroxyacetone and catalyzes the formation of riboflavin 4',5'-phosphate (aka cyclin FMN) from FAD.DAK can be inhibited by RNAi or inhibitors known in the art.
[0067] K.ERK5(MAPK7) Mitogen-activated protein kinase 7, also known as MAP kinase 7 and ERK5, is a member of the MAP kinase family. MAP kinases act as integration points for multiple biochemical signals and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcriptional regulation, and development. This kinase is specifically activated by mitogen-activated protein kinase kinase 5 (MAP2K5 / MEK5). It participates in the downstream signaling processes of various receptor molecules, including receptor tyrosine kinases and G protein-coupled receptors. In response to extracellular signals, this kinase translocates to the cell nucleus, where it regulates gene expression by phosphorylating and activating various transcription factors. Exemplary inhibitors of ERK5 include, but are not limited to, ERK5-IN-1 (11-cyclopentyl-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one), BIX 02189, XMD17-109, and XMD 8-92.
[0068] L.FRK(PTK5) Fyn-related kinase (FRK) belongs to the TYR family of protein kinases. This tyrosine kinase is a nuclear protein that functions during the G1 and S phases of cell cycle and can suppress proliferation. Exemplary inhibitors of FRK include, but are not limited to, tyrosine kinase inhibitors, such as dasatinib, motesanib (A1VIG-706), dorampimod (BIRB 796), pelitinib (EKB-569), sorafenib, vandetanib, canertinib (CI-1033) and imatinib (STI-571).
[0069] M.MAP2K7(MKK7 / GADD45b) Dual specificity mitogen-activated protein kinase kinase 7, also known as MAP kinase kinase 7 or MKK7, is an enzyme encoded by the MAP2K7 gene in humans. This protein is a member of the mitogen-activated protein kinase kinase family. MKK7 is involved in signal transduction that mediates inflammatory cytokines and cellular responses to environmental stress. MAP2K7 can be inhibited by DTP3 ((R)-2-((R)-2-acetamido-3-(4-hydroxyphenyl)propanamido)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-5-guanidinopentanamide trifluoroacetate).
[0070] N.PAK4 Serine / threonine-protein kinase PAK4 is one of six members of the PAK family of serine / threonine kinases. PAK4 localizes to the intracellular domain of the cytoplasm and the nucleus. PAK4 regulates cytoskeletal remodeling, phenotypic signaling and gene expression, affecting directional motility, invasion, metastasis, and proliferation. PAK4 can be inhibited by PF-3758309, LCH-7749944, glaucarubinone, KY-04031, KY-04045, 1-phenanthryl-tetrahydroisoquinoline derivatives, (-)-β-hydrastine, Inka1, GL-1196, GNE-2861, and microRNAs such as miR-145, miR-433, and miR-126.
[0071] O.PMVK Phosphomevalonate kinase (PMVK) is in the mevalonate pathway; it catalyzes the conversion of 5-phosphomevalonate to 5-diphosphomevalonate, which is the fifth step in the mevalonate pathway of isoprenoid biosynthesis. PMVK is a kinase that catalyzes the conversion of CSDDD_1633 (1,4-bis((2-((γ 1 -Oxidantyl)dioxo-γ 6-sulfanyl)-4-methylphenyl)amino)-5,8-dihydroxy-4a,9a-dihydroanthracene-9,10-dione), CSDDD_2260 (2,2'-((4-((2-(γ 1 -oxidanyl)-2-oxoethyl)thio)-[1,1'-biphenyl]-2,6-diyl)bis(sulfanediyl))diacetate, CSDDD_2419 ((E)-4-((2,4-dihydroxyphenyl)diazenyl)-5-methylnaphthalene-2,7-disulfonate) or luteolin (described in Boonsri et al., 2013, incorporated herein by reference).
[0072] P.PRKACB and PRKACG cAMP-dependent protein kinase catalytic subunit beta (PRKACB) is a signaling molecule for various cellular functions. cAMP exerts its effect by activating protein kinase A (PKA), which transmits signals through phosphorylation of various target proteins. The inactive holoenzyme of PKA is a tetramer composed of two regulatory subunits and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of four cAMP-bound regulatory subunits and two free monomeric catalytic subunits. AMP-dependent protein kinase catalytic subunit gamma (PRKACG) plays a role in signaling in the CCR5 pathway and gap junctions in macrophages. PRKACB or PRKACG can be inhibited by RNAi or inhibitors known in the art.
[0073] Q. PRKCI and PRKCD Protein kinase C iota (PRKCI) and protein kinase C delta (PRKCD) are members of the protein kinase C (PKC) family of serine / threonine protein kinases. The PKC family includes at least eight members that are differentially expressed and involved in a wide variety of cellular processes. This protein kinase is calcium-independent and phospholipid-dependent. It is not activated by phorbol esters or diacylglycerol. This kinase can be recruited to vesicle-tubule clusters (VTCs) by direct interaction with the small GTPase RAB2, where it phosphorylates glyceraldehyde-3-phosphate dehydrogenase (GAPD / GAPDH), which plays a role in microtubule dynamics during the early secretory pathway. This kinase was found to be required for BCL-ABL-mediated resistance to drug-induced apoptosis, thus protecting leukemic cells from drug-induced apoptosis. Exemplary inhibitors for these kinases include, but are not limited to, protein kinase inhibitors such as bisindolylmaleimide II, calphostin C, dihydrosphingosine, and LY 333531 hydrochloride. In a specific aspect, the inhibitor of PRKCI is RIDORA (Auranofin) or RXDX-108.
[0074] R.TSSK6 Testis-specific serine kinase 6 (TSSK6). The kinase encoded has a wide expression pattern, but is described as testis-specific due to its effect on fertility. TSSK6 can be inhibited by RNAi or inhibitors known in the art.
[0075] S.UCK2 Uridine-cytidine kinase 2 (UCK2) catalyzes the phosphorylation of uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), respectively. This is the first step in the production of pyrimidine nucleoside triphosphates required for RNA and DNA synthesis. In some aspects, inhibitors of UCK2 are flavokawain B or alpinetin (Malami et al., 2016).
[0076] T.ZC3HC1 Nuclear interaction partner of ALK (NIPA), also known as zinc finger C3HC type protein 1 (ZC3HC1), is exclusively expressed in nuclear subcellular location, but is universally expressed in many tissues and cell types.NIPA is a skp1 cullin F-box (SCF) type ubiquitin E3 ligase (SCFNIPA) complex protein that is involved in the regulation of entry into mitosis.ZC3HC1 can be inhibited by RNAi or inhibitors known in the art.
[0077] U. RNA interference In some embodiments, the kinase can be inhibited by RNA interference, such as siRNA or miRNA. The RNA can be siRNA, shRNA, plasmid, mRNA, miRNA, or ncRNA, particularly siRNA or miRNA therapeutic. The miRNA can be a miRNA mimic, or a miRNA precursor. The size of the RNA can be less than 100 nucleotides long, for example less than 75 nucleotides long, particularly less than 50 nucleotides long. For example, the RNA can have a length of about 10-100 nucleotides, for example 20-50 nucleotides, particularly 10-20, 15-25, 20-30, 25-35, 30-40, or 45-50 nucleotides.
[0078] RNA may be modified or unmodified. RNA may contain one or more nucleotide modifications. Such modifications may include the addition of non-nucleotide material, for example, to the end of RNA or internally (at one or more nucleotides of RNA). In some aspects, RNA molecules contain 3'-hydroxyl groups. The nucleotides in the RNA molecules of the present disclosure may also contain non-standard nucleotides, including non-natural nucleotides or deoxyribonucleotides. Double-stranded oligonucleotides may contain modified backbones, such as phosphorothioates, phosphorodithioates, or other modified backbones known in the art, or may contain non-natural internucleoside linkages. Additional modifications of siRNA (e.g., 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate internucleotide linkages, and inverted deoxyabasic residue incorporation) can be found in US Patent Application Publication No. 20040019001 and US Patent No. 6,673,611, each of which is incorporated by reference in its entirety. Taken together, all such modified nucleic acids or RNAs described above are referred to as modified siRNAs.
[0079] Preferably, RNAi can reduce protein expression by at least 10%, 20%, 30%, or 40%, more preferably at least 50%, 60%, or 70%, and even more preferably at least 75%, 80%, 90%, 95% or more.
[0080] siRNA as used in the methods or compositions described herein may include a portion that is complementary to an mRNA sequence encoded by the NCBI Reference Sequence for the kinase described. In an embodiment, the siRNA includes a double-stranded portion (duplex). In an embodiment, the siRNA is 20-25 nucleotides in length. In an embodiment, the siRNA includes a 19-21 core RNA duplex with, independently, one or two nucleotide 3' overhangs on one or both strands. In an embodiment, the overhangs are UU. The siRNA may or may not be 5' phosphorylated and may be modified with any of the modifications known in the art to improve efficacy and / or resistance to nuclease degradation. In a non-limiting embodiment, the siRNA may be administered such that it is transfected into one or more cells. In one embodiment, the siRNA may include a double-stranded RNA including a first strand and a second strand, where one strand of the RNA is 80, 85, 90, 95 or 100% complementary to a portion of an RNA transcript of a gene.
[0081] In one embodiment, the single-stranded component of the siRNA of the present disclosure is 14-50 nucleotides in length. In another embodiment, the single-stranded component of the siRNA is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides in length. In yet another embodiment, the single-stranded component of the siRNA of the present disclosure is 21 nucleotides in length. In yet another embodiment, the single-stranded component of the siRNA of the present disclosure is 22 nucleotides in length. In yet another embodiment, the single-stranded component of the siRNA of the present disclosure is 23 nucleotides in length. In one embodiment, the siRNA of the present disclosure is 28-56 nucleotides in length.
[0082] III. Treatment Methods Provided herein is a method for treating or slowing the progression of cancer in an individual, particularly cancer metastasis, comprising administering to the individual an effective amount of a kinase inhibitor, such as an inhibitor for metastasis-promoting kinases identified in the present disclosure (Table 1). Certain aspects of the present disclosure relate to a method for treating or preventing disease in a subject, which involves administering an inhibitor of metastasis-promoting kinase. The disease can be any disease that can affect a subject. In certain aspects, the disease is a hyperproliferative disease. In more particular aspects, the disease is cancer.
[0083] In some embodiments, methods are provided for inhibiting the growth and / or survival of metastatic cancer cells in the brain of a subject, comprising treating the subject with a therapeutically effective amount of an inhibitor of a kinase of Table 1. In certain embodiments, methods are provided for determining whether a brain tumor or metastatic brain tumor in a subject would receive therapeutic benefit from treatment with an inhibitor of a kinase of Table 1, e.g., by measuring expression of the kinase in the subject, e.g., in the blood of the subject.
[0084] The cancer may be a solid tumor, a metastatic cancer, or a non-metastatic cancer. In some embodiments, the cancer may originate from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gums, head, kidney, liver, lung, nasopharynx, cervix, ovary, prostate, skin, stomach, testis, tongue, or uterus. In some embodiments, the cancer is human ovarian cancer or breast cancer. Furthermore, the cancer may specifically be of the following histological types, but is not limited to: neoplasm, malignant: carcinoma; carcinoma, undifferentiated; giant cell and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; hairy epithelioma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma-cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma of adenomatous polyps; adenocarcinoma, familial polyposis coli; solid tumor; carcinomatous tumor, malignant; bronchoalveolar adenocarcinoma; breast Capillary adenocarcinoma; chromophobe carcinoma; eosinophilic carcinoma; eosinophilic adenocarcinoma; basic carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary follicular adenocarcinoma; Cystoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; invasive ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease, breast; , malignant;theca cell tumor, malignant;granulosa cell tumor, malignant;male germinoma, malignant;Sertoli cell carcinoma;Leydig cell tumor, malignant;lipid cell tumor, malignant;paraganglioma, malignant;extramammary paraganglioma, malignant;pheochromocytoma;angiocytoma;malignant melanoma;amelanotic melanoma;superficial spreading melanoma;malignant melanoma of giant pigmented nevus;epithelioid cell melanoma;blue nevus, malignant;sarcoma;fibrosarcoma;fibrous histiocytoma, malignant;myxosarcoma;liposarcoma;leiomyosarcoma;rhabdomyosarcoma;embryonal rhabdomyosarcoma;alveolar transverse sarcoma Rhabdomyosarcoma;Interstitial sarcoma;Mixed tumor, malignant;Müllerian mixed tumor;Nephroblastoma;Hepatoblastoma;Carcinosarcoma;Mesenchymal cell tumor, malignant;Brenner tumor, malignant;Phyllodes tumor, malignant;Synovial sarcoma;Mesothelioma, malignant;Dysgerminoma;Embryonal carcinoma;Teratoma, malignant;Ovarian goiter, malignant;Chorioepithelioma;Mesonephroma, malignant;Angiosarcoma;Hemangioendothelioma, malignant;Kaposi's sarcoma;Hemangiopericytoma, malignant;Lymphangiosarcoma;Osteosarcoma;Paracortical osteosarcoma;Chondrosarcoma;Chondrosarcoma, malignant;Mesenchymal chondrosarcoma;Giant cell tumor of bone;Ewing's sarcoma;Odontogenic tumors, malignant;ameloblastic odontosarcoma;ameloblastoma, malignant;ameloblastic fibrosarcoma;pinealoma, malignant;chordoma;glioma, malignant;ventricular epithelioma;astrocytoma;protoplasmic astrocytoma;fibrillary astrocytoma;astroblastoma;glioblastoma;oligodendroglioma;oligodendroglioma;primitive neuroectodermal;cerebellar sarcoma;ganglionucleoblastoma;neuroblastoma;retinoblastoma;olfactory nerve tumor;meningioma, malignant;neurofibrosarcoma;schwannoma, malignant;granular cell tumor, malignant;malignant lymphoma;Hodgkin's disease; Hodgkin's granuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other certain non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphocytic leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. Nevertheless, it will be appreciated that the present disclosure may also be used to treat non-cancerous diseases (e.g., fungal infections, bacterial infections, viral infections, and / or neurodegenerative diseases);
[0085] The tumors for which this treatment method is useful include any malignant cell type, such as those found in solid tumors or hematological tumors.Exemplary solid tumors may include, but are not limited to, tumors of organs selected from the group consisting of pancreas, colon, appendix, stomach, brain, head, neck, ovary, kidney, larynx, sarcoma, lung, bladder, melanoma, prostate and breast.Exemplary hematological tumors include bone marrow tumors, T or B cell malignancies, leukemia, lymphoma, blastoma, myeloma, etc. Further examples of cancers that may be treated using the methods provided herein include, but are not limited to, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), peritoneal cancer, gastric or stomach cancer (including gastrointestinal and gastrointestinal stromal cancer), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, various types of head and neck cancer, and melanoma.
[0086] Kinase inhibitors for this method can reduce the level of overexpressed kinases and include those generally known in the art, such as antibodies, antisense, shRNA, siRNA, or small molecule inhibitors.Administration can be by injection, such as intravenous, intrathecal, intramuscular or subcutaneous, intranasal, and oral.In many cases, especially in the case of already detected brain metastases, it is desirable to use therapeutic compositions that cross the blood-brain barrier, or administer (e.g., intrathecal or intranasal) to avoid this requirement.Combinations of treatments that provide both systemic and brain availability of therapeutic agents can also be used.
[0087] The therapeutically effective amount of the therapeutic agent can be administered by a number of routes, including parenteral administration, e.g., intravenous, intraperitoneal, intramuscular, intrasternal, or intraarticular injection or infusion. In certain aspects, the therapeutic agent is administered directly to the site of metastasis, such as the brain, or by a method that crosses the blood-brain barrier, e.g., intrathecally or intranasally. In some aspects, the therapeutic agent is administered systemically and directly to the site of metastasis, such as the brain.
[0088] A therapeutically effective amount of a kinase inhibitor is an amount that achieves a desired effect in a treated subject. For example, this can be the amount of kinase inhibitor necessary to inhibit the progression or cause regression of a cancer, or that can alleviate symptoms caused by a cancer.
[0089] Kinase inhibitors can be administered in a treatment regimen consistent with the disease, for example, in a single or several doses over a period of one to several days to improve disease state, or in periodic doses over a long period to inhibit disease progression and prevent disease recurrence. The exact dose to be used in the formulation also depends on the route of administration and the severity of the disease or disorder, and should be determined according to the judgment of the practitioner and the circumstances of each patient. The therapeutically effective amount of kinase inhibitor will depend on the subject being treated, the severity and type of the disease, and the mode of administration. The exact amount of kinase inhibitor can be easily determined by those skilled in the art based on the age, weight, sex, and physiological condition of the subject. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
[0090] A. Pharmaceutical Compositions Some of the methods described herein relate to methods that involve administration of a pharma- ceutical effective amount of a composition comprising an inhibitor of a metastasis-promoting kinase identified in this disclosure.
[0091] The use of media and agents for pharmaceutical active substances is well known in the art.Except where any conventional media or agent is incompatible with active ingredient, its use in therapeutic composition is intended.Auxiliary active ingredients can also be incorporated into the composition, which will be discussed in more detail below.For human administration, the preparation preferably meets the sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.
[0092] The present disclosure contemplates a method of using the composition that is a sterile solution for injection or for application by any other route as will be discussed in more detail below.Those skilled in the art will be familiar with the techniques for making sterile solutions for injection or for application by any other route.Sterile injections are prepared by incorporating the active compound in the required amount in a suitable solvent with various other ingredients well known to those skilled in the art.
[0093] The formulation of the composition may vary depending on the route of administration. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered and the liquid diluent first rendered isotonic with sufficient saline or glucose. In this regard, sterile aqueous media that can be used will be known to those of skill in the art in light of the present disclosure.
[0094] In addition to compounds formulated for parenteral administration, such as intravenous or intramuscular injection, other pharma- ceutically acceptable forms include formulations for administration by implantable drug delivery devices, and any other forms. Nasal solutions or sprays, aerosols, or inhalants can also be used in the present disclosure.
[0095] Oral formulations contain commonly used excipients such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, etc. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders. Those skilled in the art will be familiar with well-known techniques for preparing oral formulations.
[0096] In some embodiments, the pharmaceutical composition comprises at least about 0.1% by weight of the active agent. The composition may comprise, for example, about 0.01%. In other embodiments, the pharmaceutical composition comprises from about 2% to about 75% by weight of the composition, or from about 25% to about 60% by weight of the composition, for example, any range derivable therein.
[0097] Pharmaceutical compositions may contain various antioxidants to retard oxidation of one or more components. In addition, prevention of microbial action may be brought about by preservatives, such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparaben, propylparaben), chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof. The compositions may be stable under manufacturing and storage conditions and may be preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be understood that exotoxin contamination should be kept to a minimum at a safe level, for example, less than 0.5 ng / mg protein.
[0098] In embodiments where the composition is in liquid form, the carrier can be a solvent or dispersion medium, including, but not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes), and combinations thereof. In many cases, it will be preferable to include an isotonic agent, such as, for example, sugars, sodium chloride, or combinations thereof.
[0099] In other embodiments, nasal solutions or sprays, aerosols or inhalants may be used in the present disclosure. Nasal solutions can be aqueous solutions designed to be administered to the nasal passages in drops or sprays.
[0100] Sterile injectable solutions are prepared by incorporating the nanoparticles in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by sterilization.
[0101] 2. Route of Administration Upon formulation, the kinase inhibitors will be administered in a manner compatible with the dosage formulation, and in such amount as is therapeutically effective.
[0102] Kinase inhibitors can be administered to subjects using any method known to those skilled in the art.For example, a pharmacologic effective amount of a composition comprising nanoparticles can be administered intravenously, intracerebrally, intracranially, intrathecally, into the substantia nigra or substantia nigra region, intradermally, intraarterially, intraperitoneally, intralesionally, intratracheally, intranasally, topically, intramuscularly, intraperitoneally, subcutaneously, orally, locally, topically, by inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion that directly bathes target cells, via catheter, via lavage, in cream, in lipid composition (e.g., liposome), or by any other method or combination of the above that would be known to those skilled in the art (Remington's, 1990).In certain embodiments, the composition is administered to subjects using a drug delivery device.
[0103] 3. Dosage The pharmacologic effective amount of the kinase inhibitor is determined based on the intended purpose, for example, inhibition of cell death. The amount administered, both according to number of treatments and dose, depends on the subject being treated, the condition of the subject, the protection desired, and the route of administration. The precise amount of therapeutic agent also depends on the judgment of the practitioner and is peculiar to each individual.
[0104] For example, the dose of the therapeutic agent may be about 0.0001 milligrams to about 1.0 milligrams, or about 0.001 milligrams to about 0.1 milligrams, or about 0.1 milligrams to about 1.0 milligrams, or even about 10 milligrams, per dose. Multiple doses may also be administered. In some embodiments, the dose is at least about 0.0001 milligrams. In further embodiments, the dose is at least about 0.001 milligrams. In still further embodiments, the dose is at least 0.01 milligrams. In still further embodiments, the dose is at least about 0.1 milligrams. In more particular embodiments, the dose may be at least 1.0 milligrams. In even more particular embodiments, the dose may be at least 10 milligrams. In further embodiments, the dose is at least 100 milligrams or more.
[0105] In other non-limiting examples, dosages can also include from about 1 microgram / kg / body weight, to about 5 micrograms / kg / body weight, to about 10 micrograms / kg / body weight, to about 50 micrograms / kg / body weight, to about 100 micrograms / kg / body weight, to about 200 micrograms / kg / body weight, to about 350 micrograms / kg / body weight, to about 500 micrograms / kg / body weight, to about 1 milligram / kg / body weight, to about 5 milligrams / kg / body weight, to about 10 milligrams / kg / body weight, to about 50 milligrams / kg / body weight, to about 100 milligrams / kg / body weight, to about 200 milligrams / kg / body weight, to about 350 milligrams / kg / body weight, to about 500 milligrams / kg / body weight, to about 1000 mg / kg / body weight or more per administration, and any range derivable therein. In non-limiting examples of ranges that can be derived from the numbers recited herein, based on the above numbers, ranges such as about 5 mg / kg / body weight to about 100 mg / kg / body weight, about 5 micrograms / kg / body weight to about 500 milligrams / kg / body weight can be administered.
[0106] The doses can be repeated as determined by one of skill in the art. Thus, in some embodiments of the methods described herein, a single dose is contemplated. In other embodiments, multiple doses are contemplated. When more than one dose is administered to a subject, the time interval between doses can be any time interval as determined by one of skill in the art. For example, the time interval between doses can be about 1 hour to about 2 hours, about 2 hours to about 6 hours, about 6 hours to about 10 hours, about 10 hours to about 24 hours, about 1 day to about 2 days, about 1 week to about 2 weeks, or more, or any time interval that can be derived within any of these descriptions.
[0107] In some embodiments, the method may provide a continuous supply of the pharmaceutical composition to the patient. This may be accomplished by catheter placement followed by continuous administration of the therapeutic agent. Administration may be intraoperative or postoperative.
[0108] B. Combination Treatment Certain embodiments of the present disclosure provide a second form of one or more therapies for the treatment or prevention of a disease. For example, the disease can be a hyperproliferative disease, such as cancer.
[0109] The second form of therapy may be the administration of one or more second pharmacological agents that can be applied in the treatment or prevention of cancer. When the second therapy is a pharmacological agent, it may be administered before, simultaneously with, or after administration of the kinase inhibitor.
[0110] The interval between administration of the kinase inhibitor and the second therapy may be as determined by one of skill in the art. For example, the interval may be from minutes to weeks. In embodiments in which the agents are administered separately, one would generally ensure that no extended period of time lapses between each delivery time, so that each therapeutic agent can still exert a beneficially combined effect on the subject. For example, the interval between the therapeutic agents may be within about 12 hours to about 24 hours of each other, more preferably within about 6 hours to about 12 hours of each other. In some circumstances, the period for treatment may be extended, but where days (2, 3, 4, 5, 6, or 7) to weeks (1, 2, 3, 4, 5, 6, 7, or 8) are ineffective between each administration. In some embodiments, the timing of administration of the second therapeutic agent is determined based on the subject's response to the nanoparticles.
[0111] Various combinations may be used. For the example below, the kinase inhibitor composition is "A" and the anti-cancer therapy is "B": TIFF0007587860000002.tif17128
[0112] The administration of any compound or therapy of the present disclosure to patients follows the general protocol for administration of such compounds, taking into account the toxicity of the agent, if any.Thus, in some embodiments, there is a step of monitoring the toxicity resulting from the combination therapy.It is expected that the treatment cycle can be repeated.It is also intended that various standard therapies, as well as surgical interventions, can be applied in combination with the described therapy.
[0113] In specific aspects, it is contemplated that standard therapy includes chemotherapy, radiation therapy, immunotherapy, surgical therapy, or gene therapy, and may be used in combination with gene expression inhibitor therapy, anti-cancer therapy, or both gene expression inhibitor therapy and anti-cancer therapy, as described herein.
[0114] 1.Chemotherapy Examples of chemotherapeutic agents which may be used include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelanamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; acetogenins (particularly bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; kallistatin; CC-1065 (including its azozelesin, carzelesin, and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictin; spongiostatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobuenbiquine, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma 1I and calicheamicin omega 11); dynemicin, including dynemicin A; bisphosphonates such as clodronate; esperamicin;and neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, pothiromycin, isin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, pteropterin, and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmophor, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calsterone, dronaron propionate, propionate), epithiostanol, mepitiostane, and testolactone; antiadrenal drugs such as mitotane and trilostane; folic acid supplements such as frolinic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformitin; elliptinium acetate; epothilone; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidynin; maytansinoids such as maytansine and ansamitocin; mitoguazone; mitoxatrone; mopidamol; nitraelin; pentostatin; phenamet;Pirarubicin;rosoxantrone;podophyllic acid;2-ethylhydrazide;procarbazine;PSK polysaccharide complex;razoxane;rhizoxine;schizophyllan;spirogermanium;tenuazonic acid;triaziquone;2,2',2"-trichlorotriethylamine;trichothecenes (especially T-2 toxin, veracrine A, roridin A, and anguidine);urethane;vindesine;dacarbazine;mannomustine;mitobronitol;mitolactol;pipobroman;gacitosine;arabinoside ("Ara-C");cyclophosph amides;taxoids, such as paclitaxel and docetaxel gemcitabine;6-thioguanine;mercaptopurine;platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin;vinblastine;platinum;etoposide (VP-16);ifosfamide;mitoxantrone;vincristine;vinorelbine;novantrone;teniposide;edatrexate;daunomycin;aminopterin;xeloda;ibandronate;irinotecan (e.g., CPT-11);topoisomerase inhibitors RFS 2000; difluoromethylornithine (DMFO); retinoids, e.g., retinoic acid; capecitabine; carboplatin, procarbazine, plicomycin, gemcitabine, navelbine, farnesyl protein transferase inhibitors, transplatinum, as well as pharmaceutically acceptable salts, acids, or derivatives of any of the above.;
[0115] 2. Radiation therapy Other agents that cause DNA damage and are widely used include gamma radiation, commonly known as X-rays, and / or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging agents are also contemplated, such as microwaves, proton beam irradiation, and UV irradiation. All of these agents likely affect a wide range of damage to DNA, to the precursors of DNA, to DNA replication and repair, and to chromosome assembly and maintenance. Dose ranges for X-rays range from daily doses of 50-200 roentgens for extended periods (3-4 weeks) to single doses of 2000-6000 roentgens. Dose ranges for radioisotopes vary widely and depend on the half-life of the isotope, the strength and type of radiation emitted, and uptake by neoplastic cells.
[0116] 3. Immunotherapy Those skilled in the art will understand that immunotherapy can be used in combination or in conjunction with the method of this embodiment. In the context of cancer treatment, immunotherapy generally relies on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab (RITUXAN®) is one example. The immune effector can be, for example, an antibody specific to some marker on the surface of tumor cells. An antibody alone can be used as the effector of therapy, or the antibody can recruit other cells that actually act on cell killing. An antibody can also be conjugated to a drug or toxin (chemotherapeutic agent, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and function as a targeting agent. Alternatively, the effector can be a lymphocyte with a surface molecule that directly or indirectly interacts with the tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
[0117] Antibody-drug conjugates (ADCs) comprise monoclonal antibodies (MAbs) covalently linked to cell-killing drugs and can be used in combination therapy. This approach combines the high specificity of MAbs for their antigen target with highly potent cytotoxic drugs, resulting in "armed" MAbs that deliver payloads (drugs) to tumor cells with abundant levels of antigen. Targeted delivery of drugs also minimizes exposure of the drug in normal tissues, resulting in reduced toxicity and improved therapeutic index. Exemplary ADC drugs include ADCETRIS® (brentuximab vedotin) and KADCYLA® (trastuzumab emtansine or T-DM1).
[0118] In one aspect of immunotherapy, tumor cells must have some marker that can be targeted, i.e., not present in the majority of other cells. Many tumor markers exist, any of which may be suitable for targeting in the context of this embodiment. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis antigen, MucA, MucB, PLAP, laminin receptor, erb B, and p155. An alternative aspect of immunotherapy is to combine anti-cancer effects with immune stimulatory effects. There are also immune stimulatory molecules, including cytokines, e.g., IL-2, IL-4, IL-12, GM-CSF, gamma-IFN, chemokines, e.g., MIP-1, MCP-1, IL-8, and growth factors, e.g., FLT3 ligand.
[0119] Examples of immunotherapies include immune adjuvants, such as Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene, and aromatic compounds; cytokine therapy, such as interferon alpha, beta, and gamma, IL-1, GM-CSF, and TNF; gene therapy, such as TNF, IL-1, IL-2, and p53; and monoclonal antibodies, such as anti-CD20, anti-ganglioside GM2, and anti-p185. It is contemplated that one or more anti-cancer therapies may be used in conjunction with the antibody therapies described herein.
[0120] In some embodiments, the immunotherapy can be an immune checkpoint inhibitor. Immune checkpoints make signals (e.g., costimulatory molecules) stronger or weaker. Inhibitory immune checkpoints that can be targeted by immune checkpoint blockage include adenosine A2A receptor (A2AR), B7-H3 (also known as CD276), B and T lymphocyte attenuator (BTLA), cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152), indoleamine 2,3-dioxygenase (IDO), killer cell immunoglobulin (KIR), lymphocyte activation gene-3 (LAG3), programmed death 1 (PD-1), T cell immunoglobulin domain and mucin domain 3 (TIM-3), and V domain Ig inhibitor of T cell activation (VISTA). In particular, immune checkpoint inhibitors target the PD-1 system and / or CTLA-4.
[0121] Immune checkpoint inhibitors can be drugs, such as small molecules, recombinant forms of ligands or receptors, or in particular antibodies, such as human antibodies.Known inhibitors of immune checkpoint proteins or their analogs can be used, in particular chimeric, humanized, or human forms of antibodies.As will be understood by those skilled in the art, alternative and / or equivalent names can be used for the specific antibodies mentioned in this disclosure.Such alternative and / or equivalent names are interchangeable in the context of this specification.For example, it is known that lambrolizumab is also known as alternative and equivalent names MK-3475 and pembrolizumab.
[0122] In some embodiments, the PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partner. In a specific aspect, the PD-1 ligand binding partner is PDL1 and / or PDL2. In another embodiment, the PDL1 binding antagonist is a molecule that inhibits the binding of PDL1 to its binding partner. In a specific aspect, the PDL1 binding partner is PD-1 and / or B7-1. In another embodiment, the PDL2 binding antagonist is a molecule that inhibits the binding of PDL2 to its binding partner. In a specific aspect, the PDL2 binding partner is PD-1. The antagonist can be an antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
[0123] In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and CT-011. In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 binding antagonist is AMP-224. Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, are anti-PD-1 antibodies that may be used. Pembrolizumab, also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA®, and SCH-900475, is an exemplary anti-PD-1 antibody. CT-011, also known as hBAT or hBAT-1, is also an anti-PD-1 antibody. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor.
[0124] Another immune checkpoint that can be targeted in the methods provided herein is cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has Genbank accession number L15006. CTLA-4 is found on the surface of T cells and acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily that is expressed on the surface of helper T cells and transmits inhibitory signals to T cells. CTLA4 is similar to the T cell costimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2, respectively, on antigen-presenting cells. CTLA4 transmits inhibitory signals to T cells, while CD28 transmits stimulatory signals. Intracellular CTLA4 is also found in regulatory T cells and may be important for their function. T cell activation via the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for the B7 molecule.
[0125] In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
[0126] Anti-human CTLA-4 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present method can be generated using methods well known in the art. Alternatively, art-recognized anti-CTLA-4 antibodies can be used. An exemplary anti-CTLA-4 antibody is ipilimumab (also known as 10D1, MDX-010, MDX-101, and Yervoy®) or antigen-binding fragments and variants thereof. In other embodiments, the antibody comprises the heavy and light chain CDRs or VRs of ipilimumab. Thus, in one embodiment, the antibody comprises the CDR1, CDR2, and CDR3 domains of the VH region of ipilimumab, and the CDR1, CDR2, and CDR3 domains of the VL region of ipilimumab. In another embodiment, the antibody binds to and / or competes for binding to the same epitope on CTLA-4 as the above-mentioned antibodies. In another embodiment, the antibody has at least about 90% variable region amino acid sequence identity to an antibody described above (eg, at least about 90%, 95%, or 99% variable region identity to ipilimumab).
[0127] 4.Surgery Approximately 60% of people with cancer undergo some type of surgery, including preventive, diagnostic or staging, therapeutic, and palliative surgery. Therapeutic surgery includes resection, in which all or part of the cancerous tissue is physically removed, excised, and / or destroyed, and may be combined with other therapies, such as the treatment of the present embodiment, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapy. Tumor resection refers to the physical removal of at least a part of the tumor. In addition to tumor resection, surgical treatment includes laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs surgery).
[0128] In the removal of part or all of the cancer cells, tissue, or tumor, a cavity may be formed in the body. Treatment can be accomplished by perfusion, direct injection, or local application of the area with additional anticancer therapy. Such treatment can be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments can be at varying doses.
[0129] 5. Other agents It is contemplated that other agents may be used in combination with certain aspects of this embodiment to improve the therapeutic effect of the treatment. These additional agents include agents that act on the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of hyperproliferative cells to apoptosis-inducing agents, or other biological agents. Increasing intracellular signaling by increasing the number of GAP junctions can increase the anti-hyperproliferative effect on adjacent hyperproliferative cell populations. In other embodiments, cytostatic or differentiation agents can be used in combination with certain aspects of this embodiment to improve the anti-hyperproliferative effect of the treatment. Inhibitors of cell adhesion are contemplated to improve the effect of this embodiment. Examples of cell adhesion inhibitors are focal adhesion kinase (FAK) inhibitors and lovastatin.
[0130] IV. Kit In various aspects of the embodiment, a kit containing the therapeutic agent and / or other therapeutic and delivery agents is envisioned. In some embodiments, the embodiment contemplates a kit for preparing and / or administering the kinase inhibitor composition of the embodiment. The kit may include one or more sealed vials containing any of the pharmaceutical compositions of the embodiment. The kit may include, for example, a kinase inhibitor and reagents for preparing, formulating and / or administering the components of the embodiment or for performing one or more steps of the method of the invention. In some embodiments, the kit may also include a suitable container, which is a container that does not react with the components of the kit, such as an eppendorf tube, an assay plate, a syringe, a bottle, or a tube. The container may be made of a sterilizable material such as plastic or glass.
[0131] The kit may further include instructions outlining the procedural steps of the methods described herein, which follow substantially the same procedures as described herein or known to those of skill in the art. The instructional information may be in a computer-readable medium containing machine-readable instructions that, when executed using a computer, display an actual or virtual procedure for delivering a pharma- ceutical effective amount of a therapeutic agent. EXAMPLES
[0132] V. Working Examples The following examples are included to demonstrate preferred embodiments of the invention. Those skilled in the art should understand that the techniques disclosed in the examples which follow represent techniques found by the inventors to function well in the practice of the invention and therefore can be considered as constituting preferred modes for its practice. However, those skilled in the art should understand in light of this disclosure that numerous changes can be made in the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the invention.
[0133] Example 1 - Driver kinase screening A kinase overexpression screen was performed in vivo to identify novel drivers of brain metastasis (Figure 1). Assays were performed to determine whether kinases enhanced brain metastasis growth. Of the 17 kinase pools screened, 14 reduced mouse survival by at least 20%.
[0134] To perform the screen, retroviral plasmids encoding activated kinase open reading frames (ORFs) were stably overexpressed in MDA-MB-2131 triple-negative breast cancer parental cells (231p) and the cells were injected into the carotid artery of immunodeficient mice. MDA-MB-231 parental cells expressing luciferase, GFP, and a pool of up to 24 kinases (231p.Luciferase.GFP) were mixed with 231p cells expressing TdTomato and the empty pWZL-Neo-Myr-Flag-DEST vector (231p.TdTomato). Cells were mixed in a 3:1 ratio of kinase pool:vector and 2 x 10 6 The cells were injected into the carotid artery of nude mice.
[0135] Once animals showed neurological symptoms and their heads were determined to be highly luciferase positive by IVIS, mice were sacrificed and brain lesions were isolated using a dissecting microscope based on GFP positivity. A portion of the lesions was directly subjected to RNA extraction, while the remainder was dissociated and the cells were cultured in vitro as passage 0. gDNA was extracted from the recovered cells and the kinase vector sequence was amplified by targeted PCR. This DNA was sequenced by MiSeq to provide a quantitative readout of in vivo selection.
[0136] Tumor cells were isolated from fast-growing brain metastases and subjected to next-generation sequencing (NGS) to determine which kinases were responsible for the accelerated growth of brain metastases, resulting in the identification of 24 kinases that were enriched in vivo (Table 1). Because the screen was performed in a pooled overexpression format to simulate heterogeneity in human cancers, we next confirmed that individual kinases identified by enrichment could indeed accelerate brain metastasis growth using an in vivo gain-of-function experimental brain metastasis assay.
[0137] Some of the newly identified kinases were overexpressed singly in luciferase-labeled MDA-MB-231 parental cells. The growth of kinase-overexpressing brain metastases was analyzed compared to vector control cells (Figure 3). An in vivo imaging system (IVIS) was used to quantitate the luminescence signal generated by luciferase-expressing cancer cells. 1 x 10 per animal on day 0. 5 cells were injected and luciferase signals were normalized to day 1. It was confirmed that CDK5, PCTKI, MAPK12, LIMK2 and SPHK all significantly enhanced brain metastasis growth, whereas MARK4 did not confer a significant growth advantage (i.e., did not confer a functional hit as a single kinase).
[0138] Mice injected with kinase-overexpressing cells or the corresponding vector cells were compared for their brain metastasis-specific survival. PCTK1 overexpression shortened survival from a median of 128 days to 60 days (Figure 4A). Survival curves were significantly different (p=0.0004) according to the Mantel-Cox log-rank test. SPHK1 overexpression shortened survival from a median of 131 days to 102.5 days (Figure 4B). CDK5 overexpression shortened survival from a median of 128 days to 70 days (Figure 4C).
[0139] To test the therapeutic potential of the newly identified kinase drivers of brain metastasis growth, loss-of-function experimental brain metastasis assays were performed for four of the genes, PCTK.1, SPHK.l, and CDK5. For PCTKl, the PCTKl gene was stably knocked down by shRNA in HCC1954.Br brain-requiring cells, a HER2-positive line that forms aggressive brain metastases and has high endogenous PCTKI expression. PCTKl knockdown HCC1954.Br cells and control shRNA-transduced HCC1954.Br cells were intracarotidally injected into nude mice, respectively, and the two groups of mice were compared for survival. The PCTKl knockdown group had a significantly extended median survival time from 57.5 days to 91 days compared to the vector control shRNA group (Figure 5B).
[0140] For SPHK.l, the highly aggressive brain metastatic line MDA-MB-435 was chosen because it has high endogenous SPHKl expression. After stable shRNA-mediated knockdown of SPHK.l, mice injected with SPHK.l knockdown cells were compared for experimental brain metastasis-driven death compared to mice injected with control MDA-MB-435 cells. Indeed, SPHKl knockdown extended median mouse survival from 57.5 days to 77 days compared to controls (Figure 6B). Thus, it was clearly demonstrated that targeting two of the brain metastasis driver kinases, PCTKI and SPHKl, effectively inhibited brain metastasis and extended the survival of mice bearing brain metastases.
[0141] Furthermore, MAPK12 knockdown was found to significantly delay brain metastasis growth at an early stage in the 4T1 experimental brain metastasis model. Comparison of MAPK12 knockdown cancer cells with vector control cells showed that MAPK12 knockdown delayed brain metastasis growth (Figure 7B). Using an in vivo imaging system (IVIS), the luminescence signal generated by luciferase-expressing cancer cells was quantified. 1 x 10 per animal in a Balb / c immunocompetent mouse model. 5(C) Survival analysis of BALB / c mice injected with 4T1 cells showed that MAPK12 knockdown extended median survival from 15 to 19 days (Figure 7C).
[0142] Furthermore, CDK5 knockdown reduced cell proliferation in vitro in hypoxic conditions and significantly delayed death in the EO771 experimental brain metastasis model in a CD8 T cell-dependent manner. MTT assays demonstrated a significant reduction in in vitro cell proliferation in CDK5 knockdown cells in hypoxic conditions when compared to vector control cells (Figure 8B). Survival analysis of C57BL / 6 mice injected with EO771 cells showed that CDK5 knockdown extended median survival from 19 days to 23.5 days (Figure 8C). Survival analysis of C57BL / 6 mice injected with either control or CDK5 knockdown EO771 cells showed that there was no significant difference in mouse survival between these two groups when CD8 T cells were depleted using αCD8 antibody, suggesting that CDK5-driven brain metastasis is partially mediated through the immune system, specifically the adaptive T cell compartment (Figure 8D).
[0143] CDK5 knockdown in EO771 cells made them less sensitive to roscovitine and more sensitive to T cell cytotoxicity. CDK5 knockdown in EO771 cells made them less sensitive to the CDK5 inhibitor roscovitine compared to control cells (Figure 9A). Cytotoxic T cell killing assays showed that CDK5 knockdown in E0771 cells was more sensitive to activated T cell cytotoxicity compared to EO771 control cells (Figure 9B). T cells were activated by CD3 / CD28 antibodies (100 ng / mL) and IL-2 (10 ng / mL) before co-culture with tumor cells.
[0144] Finally, LIMK2 overexpression promoted cell proliferation in vitro in hypoxic conditions. MTT assay demonstrated a significant increase in in vitro cell proliferation in hypoxic conditions when LIMK2 was overexpressed compared to vector control cells (Figure 10B). MDA-MB-231 cells overexpressing LKB1 demonstrated a significant increase in in vitro cell proliferation in hypoxic conditions when compared to vector control cells, as shown in MTT assay (Figure 11B).
[0145] Thus, inhibition of the kinases identified by the screen significantly delays brain metastasis-associated death and is a valid therapeutic target for brain metastases.
[0146] All of the methods disclosed and claimed herein can be made and carried out without undue experimentation in light of this disclosure.Although the compositions and methods of the present invention have been described in connection with preferred embodiments, it will be apparent to those skilled in the art that modifications may be applied to the methods and steps described herein, or to the order of steps of the methods, without departing from the concept, spirit and scope of the present invention.More specifically, it will be apparent that certain agents that are chemically and physiologically related may be substituted for the agents described herein, while still achieving the same or similar results.All such similar substitutions and modifications that are apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present invention as defined by the appended claims.
[0147] References The following references, to the extent that they provide exemplary procedural or other details supplementary to the references set forth herein, are specifically incorporated herein by reference. TIFF0007587860000003.tif191128TIFF0007587860000004.tif24128
Claims
1. 1. A composition for inhibiting brain metastasis in a subject having breast cancer comprising an effective amount of a CDK5 kinase inhibitor, The CDK5 kinase inhibitor, a) roscovitine, or b) siRNA, shRNA or miRNA; The composition.
2. c) the subject was not known to have brain metastases prior to the treatment; or d) the subject was known to have one or more brain metastases prior to treatment; or e) the subject is a human; The composition of claim 1.
3. a) the CDK5 kinase inhibitor is roscovitine, or b) the CDK5 kinase inhibitor is an shRNA; The composition of claim 1.
4. CDK5 kinase inhibitors are delivered directly to the brain, or The CDK5 kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, or by direct injection; or A CDK5 kinase inhibitor is administered intravenously; or CDK5 kinase inhibitors are administered intrathecally or intranasally, The composition according to any one of claims 1 to 3.
5. The composition is administered in combination with at least a second therapeutic agent, preferably a) the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormonal therapy, antiangiogenic therapy, cytokine therapy, immunotherapy, and / or metabolic modulation, or b) the second therapeutic agent is administered simultaneously with the CDK5 kinase inhibitor; or c) the second therapeutic agent is administered sequentially to the CDK5 kinase inhibitor; The composition according to any one of claims 1 to 3.
6. 1. A composition for treating brain metastasis in a subject having breast cancer in need thereof comprising an effective amount of a CDK5 kinase inhibitor, the composition is used in combination with at least a second anti-cancer agent; The CDK5 kinase inhibitor, a) roscovitine, or b) The composition is an siRNA, an shRNA or an miRNA.
7. c) the subject was not known to have brain metastases prior to treatment, or d) the subject was known to have one or more brain metastases prior to treatment, or e) the subject is a human; The composition of claim 6.
8. a) the CDK5 kinase inhibitor is administered orally, topically, intravenously, intraperitoneally, intramuscularly, endoscopically, percutaneously, subcutaneously, locally, by direct injection, intrathecally, or intranasally; or b) the second therapeutic agent is chemotherapy, radiation therapy, gene therapy, surgery, hormonal therapy, antiangiogenic therapy, cytokine therapy, immunotherapy, and / or metabolic modulation, or c) the second therapeutic agent is administered simultaneously with the CDK5 kinase inhibitor; or d) the second therapeutic agent is administered sequentially to the CDK5 kinase inhibitor; 8. The composition of claim 6 or 7.
9. 1. A composition for treating brain metastasis in a subject with breast cancer comprising an effective amount of a CDK5 kinase inhibitor, The CDK5 kinase inhibitor, a) roscovitine, or b) The composition is an siRNA, an shRNA or an miRNA.
10. 1. A composition for treating brain metastasis in a subject with breast cancer, comprising an effective amount of a CDK5 kinase inhibitor and an anti-cancer agent, The CDK5 kinase inhibitor, a) roscovitine, or b) The composition is an siRNA, an shRNA or an miRNA.
11. d) the subject was not known to have brain metastases prior to treatment, or e) the subject was known to have one or more brain metastases prior to treatment, or f) the subject is a human; 11. The composition of claim 9 or 10.
12. the composition is administered in combination with at least a second therapeutic agent; 10. The composition of claim 9, wherein the second anti-cancer agent is chemotherapy, radiation therapy, gene therapy, surgery, hormonal therapy, anti-angiogenic therapy, or cytokine therapy, or the second therapeutic agent is radiation therapy, chemotherapy, immunotherapy, or metabolic modulation.
Citation Information
Patent Citations
The combination of purine-based CDK inhibitors and tyrosine kinase inhibitors, and their use in the treatment of proliferative disorders.
JP2010523536A
Novel heteroarylamino-3-pyrazole derivatives and pharmacologically acceptable salts thereof
WO2016195083A1
